The management of patients with platinum-resistant recurrent epithelial ovarian cancer (EOC) poses a significant challenge. Traditionally treatment has involved the use of non-platinum chemotherapeutic agents, including PEGylated liposomal doxorubicin (PLD), topotecan, gemcitabine, and paclitaxel, used as monotherapy with response rates of 10–15%, progression-free survival (PFS) of three to four months and overall survival (OS) of approximately 12 months [1]. These agents have had limited efficacy and failed to demonstrate a meaningful OS benefit at the risk of chemotherapy toxicity. Through advancements in integrated genomic analysis, an increased understanding of the underlying molecular characteristics of EOC has led to the development of various molecularly targeted strategies designed to advance the field beyond single agent chemotherapy.